

Table 2.10
WHI Outcomes by Calendar Year and Cohort

Data as of: May 10, 2026

	Calendar Year														
	1993-2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
MRC Super Cohort¹															
Number of participants with any WHI follow-up time in the interval	44174	22193	21792	21245	20682	19990	19203	18427	17525	16588	15550	14294	13035	11803	10494
Any cancer	6068	287	314	286	268	269	241	218	205	229	166	187	160	166	129
Total cardiovascular disease ²	8310	394	451	433	442	445	423	440	403	421	383	405	355	398	324
CHD ³	2369	128	151	175	150	167	179	178	156	147	145	155	118	119	126
DVT/PE	1230	88	113	102	107	85	76	74	63	74	75	69	67	67	63
Stroke	1814	126	137	131	149	150	149	167	159	180	152	159	129	151	129
Heart failure ⁴	1873	120	142	175	182	207	169	170	141	139	84	116	103	118	80
Hip fracture ⁵	894	75	74	83	108	99	98	98	94	94	82	97	115	91	85
Any fracture ⁶	11654	602	495	442	417	365	347	336	322	303	228	234	239	234	192
Number of participants with WHI or NDI⁷ follow-up time in the interval	44174	37022	36016	34858	33701	32464	31108	29813	28361	26895	25383	23555	21888	20278	18740
Death ⁸	7152	1006	1158	1157	1237	1356	1295	1452	1466	1512	1828	1667	1610	1538	1373
SRC Super Cohort^{9,10}															
Number of participants with any WHI follow-up time in the interval	117634	70831	69654	68096	66357	64378	62071	59471	56677	53566	50376	46748	43205	39523	35593
Any cancer ¹¹	19458	1060	1002	1008	872	874	866	819	735	727	630	547	497	227	189
Stroke	4359	210	263	276	299	383	402	424	474	492	454	444	463	443	415
Hip fracture ¹²	2958	340	338	333	367	338	368	385	362	410	350	433	366	400	358
Any fracture ⁶	37410	2376	1755	1723	1656	1411	1362	1317	1190	1119	839	907	810	809	696
Number of participants with WHI or NDI⁷ follow-up time in the interval	117634	99103	96416	93465	90262	86925	83352	79530	75600	71435	67244	62604	58282	53960	49692
Death ⁸	18531	2687	2951	3203	3337	3573	3822	3930	4165	4191	4640	4322	4322	4268	4203

¹ The MRC Super Cohort, or Medical Records Super Cohort, includes all WHI Hormone Trial participants and all Non-Hispanic Black/African American and Hispanic/Latina participants (identified from race/ethnicity collected on Form 2 at baseline) from the CT and OS.

² Includes MI, angina, heart failure, CABG/PTCA, carotid artery disease, PAD, stroke, DVT, PE and CVD death.

³ CHD includes MI and definite and possible CHD death.

⁴ Definite or possible decompensated heart failure adjudicated by UNC.

⁵ Includes adjudicated hip fracture through Extension Study II (2010-Present).

⁶ All non-hip fracture sites are obtained from self-reported data.

⁷ Includes follow-up time after the main study period for non-Extension study participants based on NDI searches.

⁸ Includes deaths identified through NDI searches for non-Extension study participants after the main WHI study close-out. The NDI search for 2024 only includes deaths from the 2024 early release dataset.

⁹ Cardiovascular events other than stroke are not adjudicated for SRC participants in Extension Study II (2010-Present).

¹⁰ The SRC Super Cohort includes all Non-Hispanic White, American Indian/Alaska Native, Asian/Pacific Islander, and Unknown race/ethnicity participants (identified from race/ethnicity collected on Form 2 at baseline) from the Dietary Modification Trial (not also in the Hormone Trial) and the Observational Study.

¹¹ Cancers are no longer adjudicated for SRC participants after 6/15/2023.

¹² Includes adjudicated hip fracture through Extension Study I (2005-2010) plus self-reported hip fracture during Extension Study II (2010-Present).